Back to News
Market Impact: 0.18
Pulse Biosciences Consensus Price Target Increased 12.27% to $51.82
Source: Nasdaq
Analyst EstimatesHealthcare & Biotech
The average 12-month analyst price target for Pulse Biosciences was raised 12.27% to $51.82 per share from $46.16 as of August 25, 2026. The revision indicates improved analyst valuation expectations, though it reflects aggregate consensus targets rather than a company operating update.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.28
Ticker Sentiment
PLSE0.32
More News
- ‘Like Kashmir’: How a toxic marble dump yard became a tourist spot in India
- Swiss firms plan to expand China investments as trade deal deepens ties
- Gaza doctors struggle with bereavement, overwork, trauma amid genocidal war
- Interface earnings missed by $0.01, revenue fell short of estimates
- OmniAb: A Self-Funding Option Book On 433 Partner Programs
- Regeneron: 3 Key Takeaways for Long-Term Investors
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- How to Evaluate AI Report Writers for Financial Analysis
- Augmented Intelligence: AllMind, Elevate Human Judgement With an Accessible, Powerful, Data-Driven Financial AI Toolkit